Trial Profile
A phase 1/2 trial of MOR202 for treatment of NSCLC
Status:
Planning
Phase of Trial:
Phase I/II
Latest Information Update: 10 May 2018
Price :
$35
*
At a glance
- Drugs Felzartamab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 10 May 2018 New trial record